Douglas K. Marks, MD, discusses investigational antibody–drug conjugates in HER2-positive breast cancer.
Douglas K. Marks, MD
Advertisement
Articles by Douglas K. Marks, MD
Douglas K. Marks, MD, discusses data from a small subset of patients with HER2-positive breast cancer enrolled in the PHENIX trial, which was presented at the 2019 ASCO Annual Meeting.
Douglas K. Marks, MD, clinical instructor, Department of Medicine, Perlmutter Cancer Center, NYU Langone Health, discusses the role of TKIs in HER2-positive breast cancer.
Advertisement
Latest Updated Articles
Dr. Marks on the Role of TKIs in HER2-Positive Breast CancerPublished: September 4th 2019 | Updated:
Dr. Marks on PHENIX Trial Data in HER2+ Breast CancerPublished: September 10th 2019 | Updated:
Dr. Marks on Investigational Antibody-Drug Conjugates in HER2+ Breast CancerPublished: October 21st 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5